These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9604903)

  • 1. Requirements and methods for documenting diet uniformity and compliance in drug development trials.
    Held J
    Am J Cardiol; 1998 Apr; 81(8A):31F-33F. PubMed ID: 9604903
    [No Abstract]   [Full Text] [Related]  

  • 2. Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
    Shepherd J; Olsson AG; Sacks FM; Black DM; Orloff DG; Bilheimer DW
    Am J Cardiol; 1998 Apr; 81(8A):88F-94F. PubMed ID: 9604922
    [No Abstract]   [Full Text] [Related]  

  • 3. What kinds of studies should be required to probe efficacy and safety of drugs in special populations?
    LaRosa JC; Sneider GB; Boyle C
    Am J Cardiol; 1998 Apr; 81(8A):84F-87F. PubMed ID: 9604921
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy and clinical trials.
    Seed M
    Curr Opin Lipidol; 1996 Oct; 7(5):U168-72. PubMed ID: 8937532
    [No Abstract]   [Full Text] [Related]  

  • 5. Early efficacy and safety studies.
    Sirtori CR
    Am J Cardiol; 1998 Apr; 81(8A):13F-16F. PubMed ID: 9604898
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of chart prompts to improve physician compliance with the National Cholesterol Education Program guidelines.
    Stamos TD; Shaltoni H; Girard SA; Parrillo JE; Calvin JE
    Am J Cardiol; 2001 Dec; 88(12):1420-3, A8. PubMed ID: 11741565
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipid-lowering effects of procetofene.
    Afschrift M; Mets T; Verdonk G
    Lancet; 1977 Aug; 2(8032):311. PubMed ID: 69930
    [No Abstract]   [Full Text] [Related]  

  • 8. Improving compliance in your dyslipidemic patient: an evidence-based approach.
    Becker DM; Allen JK
    J Am Acad Nurse Pract; 2001 May; 13(5):200-7. PubMed ID: 11930470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive lipid, hypertension targeting yields no benefit for some with diabetes.
    Mitka M
    JAMA; 2010 May; 303(17):1681-3. PubMed ID: 20442377
    [No Abstract]   [Full Text] [Related]  

  • 10. [KLAS [Kanazawa Lipid Assessment Survey]].
    Mabuchi H; Inazu A; Higashikata T; Nohara A; Koizumi J
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():469-76. PubMed ID: 11347115
    [No Abstract]   [Full Text] [Related]  

  • 11. A new approach to the investigation of drugs affecting lipoproteins.
    Paoletti R; Sirtori CR; Ghiselli GC; Fumagalli R
    Adv Exp Med Biol; 1978; 109():61-76. PubMed ID: 364951
    [No Abstract]   [Full Text] [Related]  

  • 12. New evidence in hypertension and hyperlipidaemia.
    Chapman N
    Heart; 2004 Jun; 90 Suppl 4(Suppl 4):iv14-7. PubMed ID: 15145906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development.
    Orloff DG
    Am J Cardiol; 2001 Feb; 87(4A):35A-41A. PubMed ID: 11243603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for Phase IV studies in the development of lipid-lowering drugs.
    Gregg RE
    Am J Cardiol; 1998 Apr; 81(8A):64F-66F. PubMed ID: 9604913
    [No Abstract]   [Full Text] [Related]  

  • 15. [Nicotinic acid and the derivative].
    Ogaki S; Matsushima T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():637-41. PubMed ID: 11347146
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hypolipemic effectiveness of using miskleron in diabetes mellitus in children and adolescents with lipodystrophies].
    Belousova LV
    Pediatriia; 1980 Jun; (6):39-41. PubMed ID: 7402836
    [No Abstract]   [Full Text] [Related]  

  • 17. [Good clinical practice. Requirements for clinical documentation on the introduction of new drugs].
    Dirach J
    Ugeskr Laeger; 1990 Apr; 152(14):992-4. PubMed ID: 2183456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypolipidemic agents and their indication].
    Teramoto T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():559-65. PubMed ID: 11347132
    [No Abstract]   [Full Text] [Related]  

  • 19. Testing pitfalls and summary of guidance in lipid management.
    Smellie WS
    BMJ; 2006 Jul; 333(7558):83-6. PubMed ID: 16825231
    [No Abstract]   [Full Text] [Related]  

  • 20. Implications of 4S evidence on baseline lipid levels.
    Durrington PN
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7661979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.